🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It’s always a good time for a reminder that HPV vaccination remains a crucial public health tool. healthline.com/health-news/hp…

Congratulations Sharonne Holtzman

Alyssa celebrates 20 years of Ovarcoming today, after being diagnosed at age 16. Let's work together to make #WorldOvarianCancerDay history. "I wouldn’t write my story any other way if I could." THIS is how #WeOvarcome! 🩵💪 🎉

Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure" Penn Medicine @nejm #immunotherapy nejm.org/doi/full/10.10…

GOAL remains: 0 in 78. Today is #WorldOvarianCancerDay Let's come together to honor all our beloved OVARCOMERS worldwide that inspire us every day. Let's continue to HOPE for a future without Ovarian Cancer. It will happen. Together We Raise Awareness. Together #WeOvarcome!🩵

Raising awareness of ovarian cancer and its symptoms with women – and clinicians – is essential if we are to reduce delays in diagnosis. World Ovarian Cancer Day & WOCCoalition #OvarianCancer #WorldOvarianCancerDay #NoWomanLeftBehind #WOCD2025

Raising awareness of ovarian cancer and its symptoms with women – and clinicians – is essential if we are to reduce delays in diagnosis. World Ovarian Cancer Day & WOCCoalition #OvarianCancer #WorldOvarianCancerDay #NoWomanLeftBehind #WOCD2025

Today is #WorldOvarianCancerDay. Real change happens when we raise awareness and empower individuals to take action against ovarian cancer. Download the toolkit: hubs.la/Q03kLsnp0 #KnowOvarian #WOCD2025

Because of the disease’s location in the body, misogyny, ageism, and other factors, it’s a sad fact that people with gyn cancers, such as #ovariancancer, may face societal stigma on top of dealing with the effects of their treatment. #WOCD2025

Don’t let docs explain away your symptoms if they persist

Promising new standard of care for our #LGSOC community! Onward, we #Ovarcome! investor.verastem.com/news-releases/…

A day to raise awareness re #ovarian cancer and celebrate incredibly strong people who are living with or lived with #ovarian cancer #GOGF committed to new tx options to improve lives of pts w #OC ⁦The GOG Foundation Inc.⁩ ⁦SGO⁩ ⁦IGCS⁩ ⁦ESMO - Eur. Oncology⁩ ⁦ASCO⁩

Another scientific advancement for our pts w/ LGSOC- a real boon for pts where more effective to options are needed SGO @GOGF IGCS ASCO ESMO - Eur. Oncology GYN Cancer | #GYNCSM

Explore expert insights in our latest CME activity on ovarian cancer. Learn how to personalize treatment for better outcomes with Drs. Kathleen N. Moore (DrKatyMoore), David M. O'Malley, & Bhavana Pothuri (Bhavana Pothuri) bit.ly/4eCQhZN

Congratulations Dr. Laura MacIsacc on a incredible year as NY OB president! Big shoes to fill for sure! Great talk about changes in abortion care- learned so much! ⁦NY OB Society⁩

Great presidential talk Dr. MacIsacc! More tidbits I learned re contemporary abortion care. So impressive to hear your career trajectory and your passion for these important services. ⁦NY OB Society⁩ ⁦Camille A. Clare MD MPH⁩ ⁦Mario M. Leitao, Jr⁩

🙌ROSELLA ! Overall survival benefit (👍PFS benefit too) with the addition of relacorilant (glucocorticoid antagonist) to nab-paclitaxel in platinum resistant #ovariancancer 🎉🔥Another big win for our patients!!! #ASCO25 #gyncsm

Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD NYU Langone Health joins Tian Zhang, MD, MHS UT Southwestern Medical Center discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no

How can oncologists tackle PARP inhibitor resistance in ovarian cancer? Hear Angeles Secord of Duke Cancer, DrDanaChase of UCLA Jonsson Comprehensive Cancer Center, Bhavana Pothuri of NYU Langone Health Premal Thaker, MD of Siteman Cancer Center and Thomas Krivak, MD of AHN Watch more here: hubs.li/Q03sDXF50

That's amazing news!!! Congrats Pedro T Ramirez and Editorial team!! 👏👏